Thursday, October 31, 2013

WORLD SERIES WATCH: Red Sox lead 6-1 in Game 6


BOSTON (AP) — A look at Game 6 of the World Series at Fenway Park on Wednesday night as the St. Louis Cardinals take on the Boston Red Sox:

___

THREE OUTS AWAY: Brandon Workman pitches a perfect eighth inning to protect a 6-1 lead for the Red Sox.

Singing, chanting crowd can hardly wait.

___

JOB WELL DONE: John Lackey exits with the bases loaded and two outs in the seventh inning, tips his cap to the cheering crowd at Fenway.

Cardinals had cut it to 6-1 on Carlos Beltran's run-scoring single, but Junichi Tazawa keeps it right there by retiring Allen Craig on a grounder.

___

RUNNING OUT OF TIME: Matt Holliday flies out with runners at the corners to end the fifth, and the Cardinals are 0 for 7 with runners in scoring position tonight. That makes them 6 for 40 (.150) in the Series. They've stranded six overall tonight.

St. Louis caught a break in the fourth when Gold Glove second baseman Dustin Pedroia botched a grounder that should have been an inning-ending double play. John Lackey, however, pitched out of trouble again by retiring Matt Adams on a liner to left and throwing a called third strike past David Freese.

___

OPENING UP: Even slumping Stephen Drew gets in on the act with a home run on the first pitch of the fourth. Red Sox lead 4-0 against Michael Wacha.

Jacoby Ellsbury also tees off for a rocket that hits the low wall in right-field near the 380-foot sign. It's a double, and Wacha gets pulled after an intentional walk to Big Papi that puts runners at the corners with two outs.

It's the third walk for Ortiz tonight — two intentional. Cardinals have obviously seen enough of him in this Series.

Ellsbury scores on Mike Napoli's single off Lance Lynn, and a walk to Jonny Gomes brings up Shane Victorino with the bases loaded again. Just an RBI single this time to make it 6-0.

___

BOBBY V: Wonder what Bobby Valentine is thinking tonight. Bet he's watching, maybe at his restaurant in Connecticut?

___

BAGS FULL: Shane Victorino does it again with the bases loaded.

His three-run double high off the Green Monster gives Boston a 3-0 lead in the third inning. It was Victorino's first hit since that go-ahead grand slam in the ALCS clincher against Detroit.

Victorino was 0 for 10 in the Series before connecting. He sat out the previous two games with a stiff back, but returned for this one and was dropped from his regular No. 2 spot to sixth in the lineup.

Jonny Gomes was hit by a pitch to load the bases — the first batter rookie Michael Wacha had ever hit in his career.

Victorino, the master of getting hit by pitches, standing almost on top of the plate. He gets ahead 2-0 in the count before pouncing on a 2-1 fastball.

Wacha doesn't have it tonight. In truth, his stuff didn't look as sharp in Game 2 at Fenway as it did during the NL playoffs, but he held Boston in check and won 4-2.

___

DIDN'T MISS A BEAT: Is anyone else amazed at how consistently hard Allen Craig has hit the ball in this Series after missing so much time with that sprained foot? DH, pinch-hitting, hasn't mattered. He's been right on Red Sox pitching. Now 2 for 2 in Game 6 and 6 for 14 in the Series.

___

QUICK WORK: John Lackey needs only five pitches to get through the third inning — even though Matt Carpenter singled with one out.

Daniel Descalso looked at three straight strikes to start the inning. After the single by Carpenter, Carlos Beltran grounded into a double play.

___

EARLY ESCAPES: Both starters pitch out of trouble in the second inning.

St. Louis put two on with none out but failed to score. John Lackey threw a two-out wild pitch that pushed the runners to second and third, then struck out Jon Jay.

That left the Cardinals 6 for 36 with runners in scoring position during the Series after setting a franchise record with a .330 mark in those situations during the regular season.

You get the feeling if the Cardinals can break through for one big hit at the right time in this game, the floodgates might open. But without it, they'll go home lamenting their lack of clutch hitting in this Series.

Matt Adams flied out to deep left, but David Freese skied to shallow center on a hittable breaking ball. Tim McCarver on Fox notes Freese, the hometown star for St. Louis in the 2011 Series, has stranded 15 runners this postseason.

Forgive us, but Freese has looked frozen all Series.

Lackey and Boston manager John Farrell all fired up.

Boston put two on to start the bottom of the second and failed to score, too. Chose not to bunt with rookie Xander Bogaerts. Not a surprise — the Red Sox don't like to sacrifice.

Wacha got two foul popups and a strikeout to keep it scoreless.

___

PACKED HOUSE: Man, oh man, are they fired up in Boston.

Red Sox looking to clinch a World Series title on their own field at fabled Fenway Park for the first time in 95 years, a stretch that's lasted from Babe Ruth to Big Papi.

Needless to say, tickets have been going for quite a pretty penny.

To do it, Boston will have to overcome rookie sensation Michael Wacha, who is 4-0 with a 1.00 ERA in four postseason starts. Can the kid do it again — under save-the-season pressure in this electric environment — and force a Game 7?

Red Sox right-hander John Lackey is trying to become the first pitcher to start and win the clinching game of a World Series for two teams. He won Game 7 of the 2002 World Series for the Anaheim Angels as a rookie against San Francisco.

And we're underway in Game 6. Lackey works a 1-2-3 first inning, helped out by a tough play from second baseman Dustin Pedroia in short right field.

___

BALLPARK BUZZ: Fenway Park was jumping early as fans poured into the old yard, hoping for a big night. Program vendors loudly reminded folks to pick up their souvenirs on the way in.

The ballpark organist tried to set a lucky tone, playing "This Magic Moment" and "Daydream Believer" and "I'm Looking Over a Four-Leaf Clover" during batting practice.

Great version of the national anthem by local band The Dropkick Murphys. Felt like last call at a packed Irish pub.

That came right after Red Sox greats Carlton Fisk and Luis Tiant threw out the first balls. Fisk, still a king at Fenway for the home run that won Game 6 of the 1975 World Series, got right in the spirit that has taken over this team — before his toss, he put on a playful beard for the ceremonies.

Source: http://news.yahoo.com/world-series-watch-red-sox-lead-6-1-024531393--spt.html
Tags: Scandal   Covered California   liberace   jets   Breaking Bad Season 6  

Cloudera pitches Hadoop for everything. Really?



When you have a big enough hammer, everything begins to look like the same kind of nail.


That's one of the potential problems with Hadoop 2.0, the greatly reworked big data processing framework that's been at the center of a whole storm of developer and end user interest. Cloudera in particular has plans to make it into a hammer for all kinds of nails.


There's no question that Hadoop 2.0 is a major leap over its predecessor. Instead of being a mere batch data processing framework for MapReduce jobs (limited, boring), it's now turned into a general framework for deploying applications across a multi-node system, with MapReduce just being one of the many possible things that can be run across those nodes (flexible, exciting).


Cloudera's clearly excited by the possibilities inherent in such an arrangement. During a keynote presentation at the O'Reilly Strata-Hadoop World conference in New York City this past Tuesday, the company described an "enterprise data hub" powered by Hadoop, one where all manner of data could be funneled in, processed in place, and extracted as needed.


Sounds great, but how feasible is it? Especially given Hadoop's status as the shiny new big data toy on the block? Such a hub may be a long way off for any company that's late to the big data party and has only just now found a place forits  multi-mega-terabyte data farms to live. Turning those "silos" (as Cloudera refers to legacy data repositories, with a near-audible sniff) into Hadoop installations isn't trivial.


The single biggest obstacle to making all that happen isn't Hadoop itself, although that's still a fairly major obstacle. In talking with vendors and users alike at Strata-Hadoop, it's clear Hadoop is still seen on all sides as a bucket of parts that needs major lifting and welding to be fully useful.


The most fruitful uses of Hadoop have been through the third parties that turn it into a ready-to-deploy product -- not just Cloudera or its quasi-rival Hortonworks, but cloud providers like Microsoft (a major Hortonworks partner), Amazon, SoftLayer, Rackspace, and just about every other name-brand cloud outfit. And few of them have yet to offer the kinds of really high-level abstraction we associate with powerful software tools, where the likes of Puppet or Python scripting are options rather than requirements.


The sheer number of moving parts and pointy edges that pop up out of Hadoop, even for smaller deployments, is still intimidating. A panel given by Dan McLary (principle product manager, Oracle) about Oracle building Hadoop appliances shed a lot of light on how much blood has to be shed, even by the likes of Oracle, to make Hadoop into a deliverable product. McLary was fairly sure over time Hadoop's rough edges would get sanded down by back-pressure from the community and vendors alike, but that time had definitely not arrived yet.


But the single biggest obstacle remains moving apps into Hadoop. The new infrastructure within Hadoop for applications, YARN, is far more open-ended than before, but it isn't trivial to rewrite an application to run there. It's not impossible there could be jury-rigs to accelerate that process -- e.g., some kind of virtualization wrapper that would allow apps to be arbitrarily shoehorned into the framework -- but that's not trivial work either.


Small wonder, then, that a great deal of work right now is being done to make Hadoop play well with existing apps -- connectors, data funnels, and the like. Very little of the discussion I encountered focused on moving existing apps into Hadoop, although few disagreed that it would happen eventually; most of it revolved around taking one's existing analytics and connecting them to Hadoop. There are, I imagine, far more people who want to do that than there are people who want to scrap everything and start over.


That said, the sheer level of bustle at the O'Reilly conference was a tipoff as to how soon that might happen. By this time next year, when the conference moves to the far-larger Javits Convention Center in Manhattan, some of Cloudera's pronouncements may seem a little less wildly optimistic. But until then, the trend right now is toward using Hadoop as a complement to existing big-data systems, not as a forklift upgrade for them.


This story, "Cloudera pitches Hadoop for everything. Really?," was originally published at InfoWorld.com. Get the first word on what the important tech news really means with the InfoWorld Tech Watch blog. For the latest developments in business technology news, follow InfoWorld.com on Twitter.


Source: http://www.infoworld.com/t/hadoop/cloudera-pitches-hadoop-everything-really-229879?source=rss_infoworld_top_stories_
Category: lakers   janelle monae   Maria de Villota   Preachers of LA   NSync  

Kerry Washington Is Pregnant!

The actress is expecting her first child! Plus, see more pregnant stars.

Source: http://www.ivillage.com/pregnant-celebrity-photos-look-whos-popping/1-b-18178?dst=iv%3AiVillage%3Apregnant-celebrity-photos-look-whos-popping-18178
Tags: bitcoin   Josh Freeman   catherine zeta jones   backstreet boys   Lady Gaga Applause  

Christina Ricci's Wedding Gown: See Her Gorgeous Givenchy Haute Couture Look!


Another childhood star, all grown up! Christina Ricci, who married James Heerdegen on Saturday, Oct. 26 in New York, shared photos of her gorgeous custom-designed Givenchy Haute Couture gown with Twitter fans on Wednesday. "I'm sorry," wrote the bride in one post. "I have to share what @riccardotisci made for me!! #iloveyouricky!"


PHOTOS: Celebrity weddings of 2013


No need to apologize! Riccardo Tisci, the creative director of Givenchy, created for Ricci, 33, a stunning and sophisticated gown with sheer, lace sleeves and cutouts at the shoulders to add enough flare to a delicate, ethereal look. The dress was comprised of white silk tulle, Chantilly lace, embroidered pearls, and satin. The lighting in one photo captured the Addams Family star's gorgeous, sheer, lace veil that cascaded from her side bun to her legs.


PHOTOS: Celebrity wedding dresses in movies and TV


Tisci, a close pal of Kanye West and Kim Kardashian, created Kim's pregnant Met Gala look. He also designed Kardashian's show-stopping, cleavage-baring dress for her recent post-baby jaunt to Paris for Fashion Week. 


PHOTOS: Secret celebrity weddings


As exclusively revealed by Us Weekly, Heerdegen and Ricci wed in an intimate ceremony at the Harold Pratt House on the Upper East Side surrounded by friends and family. The couple first met in 2011 on the set of the now-canceled series, Pan Am and Us broke news of their relationship in Feb. 2012. "My only regret was Karen's absence," said Ricci of her chihuahua, Karen; She shared another image while posing for photographer Anthony Vazquez against the backdrop of the city.


Source: http://www.usmagazine.com/celebrity-style/news/christina-riccis-wedding-gown-gorgeous-givenchy-haute-couture-20133010
Similar Articles: miguel cotto   9/11 Memorial   Sloane Stephens   Kendrick Lamar Verse   meteor shower  

Early HIV antiviral treatment found to be cost-effective in South Africa, India

Early HIV antiviral treatment found to be cost-effective in South Africa, India


[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:

30-Oct-2013



[


| E-mail

]


Share Share

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital





"Treatment as prevention" early initiation of antiretroviral therapy (ART) for HIV-infected individuals with uninfected sexual partners to prevent viral transmission appears to make economic sense, along with meeting its clinical goals of helping infected patients stay healthy and reducing transmission. A model-based analysis of data from an important clinical trial projected that early ART for such patients in both South Africa and India would be very cost-effective over the lifetime of patients. In fact, early ART in South Africa would actually save money during the first five years. The report appears in the October 31 New England Journal of Medicine.


"By demonstrating that early HIV therapy not only has long-term clinical benefits to individuals but also provides excellent economic value in both low- and middle-income countries, this study provides a critical answer to an urgent policy question," says Rochelle Walensky, MD, MPH, of the Massachusetts General Hospital (MGH) Division of Infectious Disease, corresponding author of the NEJM report. "In short, early ART is a 'triple winner': HIV-infected patients live healthier lives, their partners are protected from HIV, and the investment is superb."


In 2011 the HIV Prevention Trials Network an international research collaborative published results of a trial showing that treatment as prevention dramatically reduced the risks of viral transmission and also substantially cut the time to AIDS-related events and infections like tuberculosis in the HIV-infected patients. Called HPTN 052 and conducted at sites in nine countries, that trial was led by Myron Cohen, MD, of the University of North Carolina at Chapel Hill, and subsequently was named the 2011 Breakthrough of the Year by the journal Science. In the current National Institute of Allergy and Infectious Disease (NIAID)-supported study, the researchers worked in collaboration with the HPTN 052 trial team to analyze the trial data focusing on sites in India and South Africa, countries with the world's highest rates of HIV infection to determine whether those clinical benefits were worth the costs of ART on both short- and long-term bases.


HPTN 052 participants in the early-ART group started treatment at CD4 T cells a measure of immune system function between 350 and 550, while the control group did not start therapy until their CD4 cells dropped below 250, which was in line with World Health Organization treatment guidelines at the time. In their current analysis, the researchers used a mathematical model simulating HIV treatment and transmission and its associated health and economic outcomes to make projections for two years (the time period covered by HPTN 052), five years, and the expected lifetime of the infected participants.


The results indicated that, during the first five years, 93 percent of patients receiving early ART would survive, compared with 83 percent of those whose treatment was delayed. Life expectancy for the early-treatment group was almost 16 years, compared with nearly 14 years for the delayed treatment group. During the first five years, the potential costs of infections that were prevented by early treatment in South Africa particularly tuberculosis would outweigh the costs of ART medications, indicating that the strategy actually would save overall costs. While this was not the case for India, where costs of care for opportunistic infections are less, early ART in that country was projected to be cost-effective, according to established standards. Across patient lifetimes, early ART was determined to be very cost effective in both countries. Most of the clinical benefits were seen in the infected patients fewer illnesses and deaths and there were also added clinical and economic benefits from reducing HIV transmission.


"The reason early ART doesn't save money in the long term is actually due to its success," explains Walensky, who is a professor of Medicine at Harvard Medical School. "Patients will live much longer and take these effective medications for many years. Now that we know that early ART not only improves clinical and prevention outcomes but also is a great investment, we need to redouble international efforts to provide ART to any HIV-infected person who can benefit from it."


"Some people have questioned whether providing early ART to all who need it would be feasible in resource-limited countries," adds Kenneth Freedberg, MD, MSc, director of the MGH Medical Practice Evaluation Center and professor of Medicine at Harvard Medical School. "We've shown that in countries like South Africa, where it actually saves money in the short-term, the answer is 'yes.' We believe that continued international public and private partnerships can make this true in other countries as well. With this kind of investment, we foresee dramatic decreases in infections and illness that could save millions of lives over the next decade."


###


Additional co-authors include members of the Cost-effectiveness of Preventing AIDS Complications International team, as well as Cohen; Marybeth McCauley, MPH, FHI 360; and other members of the HPTN 052 trial team. In addition to NIAID, supporters of the study include the HIV Prevention Trials Network and the AIDS Clinical Trials Group.


Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $775 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.




[ Back to EurekAlert! ]

[


| E-mail


Share Share

]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.




Early HIV antiviral treatment found to be cost-effective in South Africa, India


[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:

30-Oct-2013



[


| E-mail

]


Share Share

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital





"Treatment as prevention" early initiation of antiretroviral therapy (ART) for HIV-infected individuals with uninfected sexual partners to prevent viral transmission appears to make economic sense, along with meeting its clinical goals of helping infected patients stay healthy and reducing transmission. A model-based analysis of data from an important clinical trial projected that early ART for such patients in both South Africa and India would be very cost-effective over the lifetime of patients. In fact, early ART in South Africa would actually save money during the first five years. The report appears in the October 31 New England Journal of Medicine.


"By demonstrating that early HIV therapy not only has long-term clinical benefits to individuals but also provides excellent economic value in both low- and middle-income countries, this study provides a critical answer to an urgent policy question," says Rochelle Walensky, MD, MPH, of the Massachusetts General Hospital (MGH) Division of Infectious Disease, corresponding author of the NEJM report. "In short, early ART is a 'triple winner': HIV-infected patients live healthier lives, their partners are protected from HIV, and the investment is superb."


In 2011 the HIV Prevention Trials Network an international research collaborative published results of a trial showing that treatment as prevention dramatically reduced the risks of viral transmission and also substantially cut the time to AIDS-related events and infections like tuberculosis in the HIV-infected patients. Called HPTN 052 and conducted at sites in nine countries, that trial was led by Myron Cohen, MD, of the University of North Carolina at Chapel Hill, and subsequently was named the 2011 Breakthrough of the Year by the journal Science. In the current National Institute of Allergy and Infectious Disease (NIAID)-supported study, the researchers worked in collaboration with the HPTN 052 trial team to analyze the trial data focusing on sites in India and South Africa, countries with the world's highest rates of HIV infection to determine whether those clinical benefits were worth the costs of ART on both short- and long-term bases.


HPTN 052 participants in the early-ART group started treatment at CD4 T cells a measure of immune system function between 350 and 550, while the control group did not start therapy until their CD4 cells dropped below 250, which was in line with World Health Organization treatment guidelines at the time. In their current analysis, the researchers used a mathematical model simulating HIV treatment and transmission and its associated health and economic outcomes to make projections for two years (the time period covered by HPTN 052), five years, and the expected lifetime of the infected participants.


The results indicated that, during the first five years, 93 percent of patients receiving early ART would survive, compared with 83 percent of those whose treatment was delayed. Life expectancy for the early-treatment group was almost 16 years, compared with nearly 14 years for the delayed treatment group. During the first five years, the potential costs of infections that were prevented by early treatment in South Africa particularly tuberculosis would outweigh the costs of ART medications, indicating that the strategy actually would save overall costs. While this was not the case for India, where costs of care for opportunistic infections are less, early ART in that country was projected to be cost-effective, according to established standards. Across patient lifetimes, early ART was determined to be very cost effective in both countries. Most of the clinical benefits were seen in the infected patients fewer illnesses and deaths and there were also added clinical and economic benefits from reducing HIV transmission.


"The reason early ART doesn't save money in the long term is actually due to its success," explains Walensky, who is a professor of Medicine at Harvard Medical School. "Patients will live much longer and take these effective medications for many years. Now that we know that early ART not only improves clinical and prevention outcomes but also is a great investment, we need to redouble international efforts to provide ART to any HIV-infected person who can benefit from it."


"Some people have questioned whether providing early ART to all who need it would be feasible in resource-limited countries," adds Kenneth Freedberg, MD, MSc, director of the MGH Medical Practice Evaluation Center and professor of Medicine at Harvard Medical School. "We've shown that in countries like South Africa, where it actually saves money in the short-term, the answer is 'yes.' We believe that continued international public and private partnerships can make this true in other countries as well. With this kind of investment, we foresee dramatic decreases in infections and illness that could save millions of lives over the next decade."


###


Additional co-authors include members of the Cost-effectiveness of Preventing AIDS Complications International team, as well as Cohen; Marybeth McCauley, MPH, FHI 360; and other members of the HPTN 052 trial team. In addition to NIAID, supporters of the study include the HIV Prevention Trials Network and the AIDS Clinical Trials Group.


Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $775 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.




[ Back to EurekAlert! ]

[


| E-mail


Share Share

]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.




Source: http://www.eurekalert.org/pub_releases/2013-10/mgh-eha102513.php
Similar Articles: Presidents Cup Streaker   lesean mccoy   Linda Ronstadt   Jenna Wolfe   meteor shower tonight  

Lyoto Machida's camp doubtful Vitor Belfort will fight him


Lyoto Machida made a booming statement at UFC Fight Night 30, finishing off a flawless victory over teammate Mark Munoz with a first-round head kick KO for his middleweight debut.


The win marked the last bout on Machida's contract and rocketed the former UFC light heavyweight champion into an immediate top-5 ranking in the UFC's 185-pound division. Afterward, with his eyes planted firmly on a title, the reinvigorated contender called out Vitor Belfort, the division's No. 2 ranked fighter who's currently slated to fight at light heavyweight against Dan Henderson.


"Vitor Belfort is the best option for me right now," Machida (20-4) told MMAFighting.com. "I want to fight him. It would be the best fight for me right now because he's well ranked in the middleweight division.


"Even if Vitor loses to Dan Henderson, I'd want to fight him in our weight class."


It's a match-up that certainly makes sense. UFC middleweight champion Chris Weidman and the division's former kingpin Anderson Silva are tied up until December 28, at the earliest, while Belfort (23-10) is the owner of what may be the division's most impressive current streak, having knocked out Michael Bisping and Luke Rockhold in back-to-back spectacular performances.


Nonetheless, Machida's management voiced doubts about the potential bout on Wednesday's episode of UFC Tonight.


According to Ariel Helwani, Machida's manager Jorge Guimaraes believes the match-up won't take place, simply because Belfort won't accept the fight.


Belfort has turned down fights in the past, with the most recent example being a proposed match-up against Tim Kennedy. It's largely the reason he's fighting Henderson at light heavyweight, as Belfort voiced hesitance about relinquishing his status as No. 1 middleweight contender, much to the displeasure of UFC President Dana White, who recently said that the Brazilian "drives me crazy."


Even still, Machida continues to await his next marching orders while Belfort and Henderson are set to square off in the main event of UFC Fight Night 32 on November 9, 2013 at the Goiania Arena in Goiania, Brazil.


Source: http://www.mmafighting.com/2013/10/30/5048434/lyoto-machidas-camp-doubtful-vitor-belfort-will-fight-him
Tags: Giraffe   Donatella Versace   Nokia   Amish Mafia   megyn kelly  

House Republican backs Dem immigration bill

(AP) — House Democrats pushing a comprehensive approach to overhauling the nation's immigration system picked up the support of a third Republican on Wednesday.

Freshman Rep. David Valadao of California said he would back a measure that would provide a path to citizenship for the 11 million immigrants living here illegally and tighten border security. Valadao joins Republicans Reps. Jeff Denham of California and Ileana Ros-Lehtinen of Florida in announcing support for the Democratic bill.

Valadao signaled that his support for the measure was meant to increase pressure on House Republican leaders to act before year's end. The Senate passed a comprehensive bill in June, but prospects remain murky for any House vote with just a few legislative weeks left.

"I have been working with my colleagues on both sides of the aisle to find common ground on the issue of immigration reform." Valadao said in a statement. "Recently, I have focused my efforts on joining with likeminded Republicans in organizing and demonstrating to Republican leadership broad support within the party to address immigration reform in the House by the end of the year."

Valadao said the House cannot wait on dealing with immigration.

Most House Republicans reject a comprehensive approach as well as the Senate bill, with many question offering citizenship to people who broke U.S. immigration laws to be in this country. The House Judiciary Committee has moved forward with individual, single-issue immigration bills.

Although House Republican leaders say they want to resolve the issue, which has become a political drag for the GOP, many rank-and-file House Republicans have shown little inclination to deal with it. The bitter standoff with President Barack Obama on the budget and near default further angered House Republicans, who have resisted any move that might give Obama an immigration overhaul, the top item on his second-term domestic agenda.

Numerous House Republicans are wary of passing any immigration legislation that would set up a conference with the Senate, fearing that they would lose out in final negotiations.

The Senate bill, strongly backed by the White House, includes billions for border security, a reworked legal immigration system to allow tens of thousands of high- and low-skilled workers into the country and a 13-year path to citizenship for the 11 million immigrants already here illegally.

The bill from House Democrats jettisoned the border security provision and replaces it with the Homeland panel's version. That bill, backed by conservative Republicans and liberal Democrats, would require the homeland security secretary to develop a strategy to gain operational control of the border within five years and a plan to implement the strategy. It calls on the Government Accountability Office, Congress' auditing and investigative arm, to oversee the steps being taken.

The bill doesn't call for new spending, in contrast to the Senate bill, which includes $46 billion in new spending on drones, helicopters and other technology, a doubling of agents patrolling the border with Mexico and hundreds of miles of new fencing.

House Democratic leader Nancy Pelosi of California said she was optimistic, although there has been no overt effort by House Republican leaders to move toward a vote.

"If this bill were brought to the floor, or a bill that is positive goes in a forward direction, while it might not meet every standard that we have in our bill, but takes us to the conference table in a positive way, we would be very enthusiastic about that," Pelosi told reporters. "So as I said to the speaker: 'However you want to do it, let's just do it.'"

Associated PressSource: http://hosted2.ap.org/APDEFAULT/89ae8247abe8493fae24405546e9a1aa/Article_2013-10-30-US-Congress-Immigration/id-41e699c7d95a4387b92a7ab2a2e4df46
Category: Real Madrid   Obama impeachment   trent richardson   amber heard   Whitey Bulger